Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.
In this study, peripheral blood samples of PCOS patients were collected before and after intervention. Flow cytometry was used to detect the antigenic antibody reaction between the surface differentiation antigen of lymphocyte membrane and fluorescently labeled antibodies in human peripheral blood, and the unlabeled cells were dissolved. The number and percentage of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metformin therapy | Experimental | Metformin intervention, 1000mg daily for the first week, 1500mg daily starting in the second week until six months of treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug | Take metformin for six months. |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| The number of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry. | Flow cytometry was used to detect the antigenic antibody reaction between the surface differentiation antigen of lymphocyte membrane and the fluorescently labeled antibody in human peripheral blood, and the unlabeled cells were dissolved. | Samples to be collected once per participant within 7 days of enrollment. |
| The percentage of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry. | Flow cytometry was used to detect the antigenic antibody reaction between the surface differentiation antigen of lymphocyte membrane and the fluorescently labeled antibody in human peripheral blood, and the unlabeled cells were dissolved. | Samples to be collected once per participant within 7 days of enrollment. |
| Measure | Description | Time Frame |
|---|---|---|
| Homeostasis model assessment of insulin resistance | insulin resistance index | Within 7 days of enrollment. |
| body mass index | body mass index (kg/m2) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Manna Zhang, doctor | Contact | +8613774448495 | mannazhang@126.com |
| Name | Affiliation | Role |
|---|---|---|
| Manna Zhang, doctor | Shanghai 10th People's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Endocrinology, Shanghai Tenth People's Hospital | Recruiting | Shanghai | 200072 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Within 7 days of enrollment. |
| menstrual frequency | number of menstruation in a year | Within 7 days of enrollment. |
| fasting glucose | fasting glucose (mmol/L) | Within 7 days of enrollment. |
| fasting insulin | fasting insulin (mmol/L) | Within 7 days of enrollment. |
| Total cholesterol | Total cholesterol (mmol/L) | Within 7 days of enrollment. |
| Triglycerides | Triglycerides (mmol/L) | Within 7 days of enrollment. |
| HDL-c | HDL-c (mmol/L) | Within 7 days of enrollment. |
| LDL-c | LDL-c (mmol/L) | Within 7 days of enrollment. |
| total testosterone | total testosterone (nmol/L) | Within 7 days of enrollment. |
| free testosterone | free testosterone (nmol/L) | Within 7 days of enrollment. |
| Sex hormone-binding globulin | Sex hormone-binding globulin (nmol/L) | Within 7 days of enrollment. |
| Androstenedione | Androstenedione (ng/ml) | Within 7 days of enrollment. |
| Dehydroepiandrosterone | Dehydroepiandrosterone (ug/dl) | Within 7 days of enrollment. |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |